Jeon, M. Y., Kim, B. K., Lee, J. S., Lee, H. W., Park, J. Y., Kim, D. Y., . . . Kim, S. U. (2021). Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clinical and molecular hepatology, 27(2), 295-304. https://doi.org/10.3350/cmh.2020.0216
Chicago Style (17th ed.) CitationJeon, Mi Young, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, and Seung Up Kim. "Negligible Risks of Hepatocellular Carcinoma During Biomarker-defined Immune-tolerant Phase for Patients with Chronic Hepatitis B." Clinical and Molecular Hepatology 27, no. 2 (2021): 295-304. https://doi.org/10.3350/cmh.2020.0216.
MLA (9th ed.) CitationJeon, Mi Young, et al. "Negligible Risks of Hepatocellular Carcinoma During Biomarker-defined Immune-tolerant Phase for Patients with Chronic Hepatitis B." Clinical and Molecular Hepatology, vol. 27, no. 2, 2021, pp. 295-304, https://doi.org/10.3350/cmh.2020.0216.